With its campus expanding as gene therapy booms, Aldevron brings in a top exec from a medtech giant to steer the course
We now know where Kevin Ballinger was headed when he unexpectedly handed in his resignation earlier this month as one of the top EVPs at medtech giant Boston Scientific, where he’s spent the last 25 years.
Ballinger is landing in Fargo, ND, where he’s now taking the reins as the new CEO at Aldevron, one of the world’s top manufacturers of plasmid DNA, mRNA, CRISPR/Cas9, vectors and more, serving the burgeoning world of gene therapy developers around the world.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 112,600+ biopharma pros reading Endpoints daily — and it's free.